Cyfuse Biomedical K.K. (TYO:4892)
Japan
· Delayed Price · Currency is JPY 621.00
-19.00 (-2.97%)
Mar 9, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 230 | 54 | 61 | 374 | 708 | Upgrade
|
| Revenue Growth (YoY) | 325.93% | -11.47% | -83.69% | -47.17% | 416.79% | Upgrade
|
| Cost of Revenue | 117 | 38 | 23 | 133 | 137 | Upgrade
|
| Gross Profit | 113 | 16 | 38 | 241 | 571 | Upgrade
|
| Selling, General & Admin | 942 | 428 | 351 | 346 | 500 | Upgrade
|
| Research & Development | - | 469 | 375 | 303 | - | Upgrade
|
| Operating Expenses | 942 | 912 | 735 | 666 | 500 | Upgrade
|
| Operating Income | -829 | -896 | -697 | -425 | 71 | Upgrade
|
| Interest Expense | -15 | -10 | -10 | -7 | -5 | Upgrade
|
| Interest & Investment Income | 3 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -1 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 80 | 36 | 121 | - | 78 | Upgrade
|
| EBT Excluding Unusual Items | -761 | -870 | -586 | -433 | 144 | Upgrade
|
| Other Unusual Items | - | - | - | -38 | - | Upgrade
|
| Pretax Income | -761 | -870 | -586 | -471 | 144 | Upgrade
|
| Income Tax Expense | 2 | 2 | 3 | 2 | 2 | Upgrade
|
| Net Income to Company | -763 | -872 | -589 | -473 | 142 | Upgrade
|
| Net Income | -763 | -872 | -589 | -473 | 142 | Upgrade
|
| Net Income to Common | -763 | -872 | -589 | -473 | 142 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 8 | 8 | 3 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 8 | 8 | 3 | 1 | Upgrade
|
| Shares Change (YoY) | 9.33% | 3.05% | 192.85% | 432.99% | - | Upgrade
|
| EPS (Basic) | -86.69 | -108.31 | -75.39 | -177.31 | 283.72 | Upgrade
|
| EPS (Diluted) | -86.69 | -108.31 | -75.39 | -177.31 | 283.72 | Upgrade
|
| Free Cash Flow | -581 | -768 | -581 | -631 | - | Upgrade
|
| Free Cash Flow Per Share | -66.01 | -95.40 | -74.37 | -236.54 | - | Upgrade
|
| Gross Margin | 49.13% | 29.63% | 62.30% | 64.44% | 80.65% | Upgrade
|
| Operating Margin | -360.44% | -1659.26% | -1142.62% | -113.64% | 10.03% | Upgrade
|
| Profit Margin | -331.74% | -1614.82% | -965.57% | -126.47% | 20.06% | Upgrade
|
| Free Cash Flow Margin | -252.61% | -1422.22% | -952.46% | -168.72% | - | Upgrade
|
| EBITDA | -792 | -858 | -657 | -362 | - | Upgrade
|
| EBITDA Margin | - | - | - | -96.79% | - | Upgrade
|
| D&A For EBITDA | 37 | 38 | 40 | 63 | - | Upgrade
|
| EBIT | -829 | -896 | -697 | -425 | 71 | Upgrade
|
| EBIT Margin | - | - | - | -113.64% | 10.03% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 1.39% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.